JP2002322078A - Skin care preparation - Google Patents
Skin care preparationInfo
- Publication number
- JP2002322078A JP2002322078A JP2001127151A JP2001127151A JP2002322078A JP 2002322078 A JP2002322078 A JP 2002322078A JP 2001127151 A JP2001127151 A JP 2001127151A JP 2001127151 A JP2001127151 A JP 2001127151A JP 2002322078 A JP2002322078 A JP 2002322078A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- glycogen
- ethanol
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 60
- 229920002527 Glycogen Polymers 0.000 claims abstract description 41
- 229940096919 glycogen Drugs 0.000 claims abstract description 39
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 22
- 239000012046 mixed solvent Substances 0.000 claims abstract description 4
- 239000011347 resin Substances 0.000 claims abstract description 4
- 229920005989 resin Polymers 0.000 claims abstract description 4
- 238000005342 ion exchange Methods 0.000 claims abstract description 3
- 238000001179 sorption measurement Methods 0.000 claims abstract description 3
- 241000544061 Cuculus canorus Species 0.000 claims description 18
- 235000020638 mussel Nutrition 0.000 claims description 16
- 238000000605 extraction Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 239000007864 aqueous solution Substances 0.000 abstract description 8
- 230000001976 improved effect Effects 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 2
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- 239000000306 component Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000008213 purified water Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000037303 wrinkles Effects 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 235000005822 corn Nutrition 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 8
- -1 Polyoxyethylene Polymers 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241000209094 Oryza Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 229960002216 methylparaben Drugs 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000005893 Pteridium aquilinum Species 0.000 description 3
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 3
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 244000104272 Bidens pilosa Species 0.000 description 2
- 235000010662 Bidens pilosa Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QRTADFOPPOKFDH-UHFFFAOYSA-N 20,21-dihydroxyhenicosanoic acid Chemical compound OCC(O)CCCCCCCCCCCCCCCCCCC(O)=O QRTADFOPPOKFDH-UHFFFAOYSA-N 0.000 description 1
- IHHWIRIIIZBIDV-UHFFFAOYSA-N 4,5-dihydroxy-3-phenylchromen-2-one Chemical compound OC=1C=2C(O)=CC=CC=2OC(=O)C=1C1=CC=CC=C1 IHHWIRIIIZBIDV-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical class C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000237524 Mytilus Species 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、肌荒れや皮膚の損
傷及び老化の防止,改善効果が相乗的に向上した皮膚外
用剤に関する。さらに詳しくは、カッコンの抽出物及び
抽出分画物より選択した1種又は2種以上、もしくはそ
の有効成分である4',7-ジヒドロキシイソフラボンと、
グリコーゲンとを併用して成る皮膚外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin which synergistically improves the effects of preventing and improving rough skin, skin damage and aging. More specifically, one or two or more selected from extracts and extract fractions of cuckoo, or 4 ', 7-dihydroxyisoflavone which is an active ingredient thereof,
The present invention relates to an external preparation for skin which is used in combination with glycogen.
【0002】[0002]
【従来の技術】加齢や紫外線曝露,皮膚組織内において
発生する活性酸素種等による酸化的ストレス、薬物や種
々のアレルゲンとの接触などにより、皮膚の炎症反応や
皮膚の損傷及び老化が進行することが知られている。こ
れまで皮膚外用剤の分野では、かかる皮膚の炎症や老化
を防止するべく、活性酸素種消去剤や抗炎症剤,抗アレ
ルギー剤等多くの生理活性成分の探索及び検討がなされ
てきた。近年は、消費者の天然志向及び植物志向を反映
してか、かかる成分を植物に求める傾向が強くなってい
る。2. Description of the Related Art Due to aging, exposure to ultraviolet rays, oxidative stress due to reactive oxygen species generated in skin tissues, contact with drugs and various allergens, skin inflammatory reactions, skin damage and aging progress. It is known. In the field of skin external preparations, many physiologically active ingredients such as active oxygen species scavengers, anti-inflammatory agents and anti-allergic agents have been searched and examined in order to prevent such skin inflammation and aging. In recent years, there has been a strong tendency to seek such components from plants, reflecting the natural and plant consciousness of consumers.
【0003】しかしながら、すでに報告されている植物
起源の上記成分の中には、活性が低いため、皮膚外用剤
に配合して十分な作用効果を得るにはかなりの高濃度を
要したり、安定性や安全性上問題があったり、皮膚外用
剤に好ましくない色や臭いを付与してしまうものがあっ
たりして、皮膚外用剤に配合した際に、製剤安定性及び
安全性と、作用効果のすべての面で満足できるものは少
ないのが現状であった。また皮膚の炎症反応や損傷,老
化等は、種々の要因が複雑に関与し合って進行するた
め、前記反応の一部の過程のみに作用する物質を用いて
も十分な効果は得られなかった。[0003] However, among the above-mentioned components of plant origin which have already been reported, due to their low activity, a fairly high concentration is required to obtain a sufficient effect when incorporated into a skin external preparation, There is a problem in terms of stability and safety, and there is something that gives an undesired color or odor to the external preparation for skin. At present, there are few things that can be satisfied in all aspects. In addition, the skin inflammatory reaction, damage, aging, and the like progress due to various factors involved in a complex manner, and thus, even if a substance that acts only on a part of the reaction is not sufficiently effective. .
【0004】[0004]
【発明が解決しようとする課題】そこで本発明において
は、複雑な皮膚の炎症性反応等を抑制し、肌荒れや皮膚
の損傷及び老化の防止,改善効果が相乗的に向上した皮
膚外用剤を得ることを目的とした。Therefore, in the present invention, an external preparation for skin which suppresses complex skin inflammatory reactions and the like, and has a synergistically improved effect of preventing and improving skin roughness, skin damage and aging is obtained. It was aimed at.
【0005】[0005]
【課題を解決するための手段】上記課題を解決するべく
種々検討したところ、本発明者らはカッコン(Pueraria
e Radix)の抽出物及び抽出分画物に高い線維芽細胞賦
活作用及びコラーゲン産生促進作用を見いだし、さらに
これらより選択した1種又は2種以上と、グリコーゲン
とを併用して皮膚外用剤に含有させることにより、良好
な抗炎症作用及び皮膚の修復作用が得られ、肌荒れや皮
膚の損傷及び老化の防止,改善効果の相乗的な向上が得
られることを見いだし、本発明を完成するに至った。The present inventors have made various studies to solve the above-mentioned problems, and as a result, the present inventors have found that Pueraria
e Radix ) extract and extract have high fibroblast activating and collagen production-promoting effects, and one or more selected from these, combined with glycogen, are contained in a skin external preparation. By doing so, it was found that a good anti-inflammatory action and a skin repair action were obtained, and a synergistic improvement in the effects of preventing and improving skin roughness, skin damage and aging was obtained, and completed the present invention. .
【0006】特に、カッコン抽出物及び抽出分画物とし
て、4',7-ジヒドロキシイソフラボン(ダイゼイン)含
有量の高いものを用いると、良好な効果が得られ、また
4',7-ジヒドロキシイソフラボン自体と併用してもよ
い。[0006] In particular, when a high content of 4 ', 7-dihydroxyisoflavone (daidzein) is used as the cuckoo extract and extract fraction, a good effect can be obtained.
It may be used in combination with 4 ', 7-dihydroxyisoflavone itself.
【0007】なお、カッコン抽出物については、ムコ多
糖断片化抑制,活性酸素消去,抗酸化作用(特開平6−
24937)、脂肪合成促進作用(特開平11−199
499)、毛乳頭活性化作用(特開平11−24082
3)が開示され、ヒアルロン酸産生促進作用も報告され
ている(日本薬学会第120年会講演要旨集2,第58
ページ,2000年)が、I型コラーゲンの産生促進作
用については全く知られていない。さらに、7-イソプロ
ポキシイソフラボンの代謝物についてI型コラーゲンの
合成促進作用が報告されている(Calcified Tissue Int
ernational 55(5) 356-362 (1994))が、カッコン抽出
物中の4',7-ジヒドロキシイソフラボンについては抗ア
セチルコリン作用を有することは周知であるものの、か
かる報告はこれまでなされていない。[0007] In addition, the extract of cucumbers, mucopolysaccharide fragmentation suppression, active oxygen scavenging, antioxidant activity (Japanese Unexamined Patent Publication No.
24937), a fat synthesis promoting action (JP-A-11-199)
499), dermal papilla activating action (JP-A-11-24082)
No. 3) has been disclosed, and a hyaluronic acid production promoting action has also been reported (Abstracts of the 120th Annual Meeting of the Pharmaceutical Society of Japan, No. 58)
Page, 2000), but nothing is known about the type I collagen production promoting action. Furthermore, a metabolite of 7-isopropoxy isoflavone has been reported to promote the synthesis of type I collagen (Calcified Tissue Int.
Although it is well known that E. ernational 55 (5) 356-362 (1994) has an antiacetylcholine effect with respect to 4 ', 7-dihydroxyisoflavone in cuckoo extract, such a report has not been made so far.
【0008】また、グリコーゲンについては、保湿剤と
しての利用(特開昭62−178505,特開昭63−
290809)や、線維芽細胞増殖作用(特開平11−
255657)などが報告されている。しかしながら、
カッコンの抽出物もしくは抽出分画物又は4',7-ジヒド
ロキシイソフラボンと、グリコーゲンとを併用すること
により得られる本発明の効果は、これまで全く示唆すら
されていない。[0008] Glycogen is used as a humectant (Japanese Patent Application Laid-Open No. 62-178505,
290809) and a fibroblast proliferation action (Japanese Unexamined Patent Application Publication No.
255657). However,
The effect of the present invention obtained by using a combination of glycogen and an extract or extract fraction of cuckoo or 4 ', 7-dihydroxyisoflavone has not been suggested yet.
【0009】[0009]
【発明の実施の形態】本発明において用いるカッコン
(Puerariae Radix)は、マメ科(Leguminosae)に属す
る落葉藤本であるクズ(Pueraria lobata Ohwi)の周皮
を除いた根であり、日本産,韓国産及び中国産の角カッ
コン,板カッコン及び粉カッコンを用いることができ
る。BEST MODE FOR CARRYING OUT THE INVENTION Cuckoo ( Puerariae Radix ) used in the present invention is a root excluding the pericarp of kudzu ( Pueraria lobata Ohwi), which is a deciduous fujimoto belonging to the leguminous family ( Leguminosae ), and is produced in Japan and Korea. And square brackets, board brackets and powdered brackets produced in China can be used.
【0010】カッコン(Puerariae Radix)は、生のま
ま抽出に供してもよいが、抽出効率を考えると、細切,
乾燥,粉砕等の処理を行った後に抽出を行うことが好ま
しい。抽出は、抽出溶媒に浸漬して行う。抽出効率を上
げるため撹拌を行ったり、抽出溶媒中でホモジナイズし
てもよい。抽出温度としては、5℃程度から抽出溶媒の
沸点以下の温度とするのが適切である。抽出時間は抽出
溶媒の種類や抽出温度によっても異なるが、4時間〜1
4日間程度とするのが適切である。[0010] Cuckoo ( Puerariae Radix ) may be subjected to extraction as it is, but in consideration of extraction efficiency, it must be chopped,
It is preferable to perform extraction after performing processing such as drying and pulverization. The extraction is performed by immersion in an extraction solvent. Stirring may be performed to increase the extraction efficiency, or homogenization may be performed in an extraction solvent. It is appropriate that the extraction temperature is set to a temperature of about 5 ° C. to the boiling point of the extraction solvent or lower. The extraction time varies depending on the type of the extraction solvent and the extraction temperature, but is from 4 hours to 1 hour.
It is appropriate to make it about four days.
【0011】抽出溶媒としては、水の他、メタノール,
エタノール,プロパノール,イソプロパノール等の低級
アルコール、1,3-ブチレングリコール,プロピレングリ
コール,ジプロピレングリコール,グリセリン等の多価
アルコール、エチルエーテル,プロピルエーテル等のエ
ーテル類、酢酸エチル,酢酸ブチル等のエステル類、ア
セトン,エチルメチルケトン等のケトン類などの極性有
機溶媒を用いることができ、これらより1種又は2種以
上を選択して用いる。また、生理食塩水,リン酸緩衝
液,リン酸緩衝生理食塩水等を用いてもよい。As an extraction solvent, in addition to water, methanol,
Lower alcohols such as ethanol, propanol and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin; ethers such as ethyl ether and propyl ether; esters such as ethyl acetate and butyl acetate And polar organic solvents such as ketones such as acetone and ethyl methyl ketone, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used.
【0012】カッコン(Puerariae Radix)の上記溶媒
による抽出物は、そのままでも本発明に係る皮膚外用剤
に含有させることができるが、濃縮,乾固したものを水
や極性溶媒に再度溶解したり、或いはこれらの生理作用
を損なわない範囲で脱色,脱臭,脱塩等の精製処理を行
ったり、カラムクロマトグラフィー等による分画処理を
行った後に用いてもよい。特に、イオン交換吸着樹脂に
吸着させた後、水・エタノール混合溶媒にて順次溶出し
た際、50容量%〜99.5容量%エタノール水溶液に
より溶出される画分が4',7-ジヒドロキシイソフラボン
を最も多く含有し、コラーゲン産生促進作用の点から最
も好ましく用いられる。イオン交換樹脂としては、DI
AION MCIゲル HP-20(三菱化学株式会社
製)等が好ましく用いられる。カッコンの前記抽出物や
その処理物及び分画物は、各処理及び分画の後凍結乾燥
し、用時に溶媒に溶解して用いることもできる。また、
リポソーム等のベシクルやマイクロカプセル等に内包さ
せて用いることもできる。The extract of Puerariae Radix with the above-mentioned solvent can be contained in the external preparation for skin according to the present invention as it is, but the concentrated and dried extract can be redissolved in water or a polar solvent. Alternatively, it may be used after performing a purification treatment such as decolorization, deodorization, desalting or the like within a range that does not impair these physiological actions, or after performing a fractionation treatment by column chromatography or the like. In particular, after being adsorbed on an ion exchange adsorption resin, when sequentially eluted with a mixed solvent of water and ethanol, the fraction eluted with a 50% to 99.5% by volume aqueous ethanol solution contains 4 ′, 7-dihydroxyisoflavone. It is most contained and is most preferably used in terms of collagen production promoting action. As the ion exchange resin, DI
AION MCI gel HP-20 (manufactured by Mitsubishi Chemical Corporation) or the like is preferably used. The extract of the parentheses, the processed product thereof, and the fractionated product may be freeze-dried after each treatment and fractionation, and may be used by dissolving in a solvent at the time of use. Also,
It can also be used by being encapsulated in vesicles such as liposomes or microcapsules.
【0013】また本発明においては、上記したカッコン
の抽出物又はその分画物の替わりに、精製した4',7-ジ
ヒドロキシイソフラボンを用いてもよい。In the present invention, purified 4 ', 7-dihydroxyisoflavone may be used in place of the above-mentioned extract of cuckoo or a fraction thereof.
【0014】本発明において、上記カッコン(Pueraria
e Radix)の抽出物及び抽出分画物の1種又は2種以
上、もしくは4',7-ジヒドロキシイソフラボンと併用す
るグリコーゲンは、α-1,4-グルカン鎖にα-1,6結合に
よるグルカンの分枝を有するホモ多糖であり、動物の肝
臓や筋肉,イガイ等貝類の貝肉,トウモロコシの種子,
米粒,酵母等より抽出,調製したものを用いることがで
きる。また、前記動植物等を基原とする市販品を用いて
もよい。それらの中でも、ムラサキイガイ(Myti lus ed
ulis)等イガイ類から抽出したグリコーゲンが優れた皮
膚の損傷修復作用を有するため、最も好ましく使用でき
る。In the present invention, the parentheses ( Pueraria)
e Radix ), glycogen used in combination with one or more of the extract and extract fraction, or in combination with 4 ', 7-dihydroxyisoflavone, is a glucan by α-1,6 bond to α-1,4-glucan chain. Is a homopolysaccharide having the branches of animal, liver, muscle, mussel shells such as mussels, corn seeds,
Extracted and prepared from rice grains, yeast, etc. can be used. Alternatively, a commercially available product based on the above-mentioned animals and plants may be used. Among them, mussels ( Myti lus ed
Glycogen extracted from mussels such as ulis ) is most preferably used since it has an excellent skin damage repair effect.
【0015】グリコーゲンは、動植物の各組織を細切又
は粉砕して精製水に浸漬して抽出する。精製水に浸漬し
た後コロイド破砕機や超音波破砕機などにより破砕して
もよい。遠心分離して得た抽出液を加熱処理及び/又は
トリクロロ酢酸等で処理してタンパク質を除去した後、
メタノール,エタノール,アセトン等の有機溶媒を添加
してグリコーゲンを沈殿させるか、或いは濃縮した後、
噴霧,乾燥することにより、グリコーゲンを回収するこ
とができる。Glycogen is extracted by slicing or pulverizing tissues of animals and plants and immersing them in purified water. After immersion in purified water, it may be crushed by a colloid crusher or an ultrasonic crusher. After removing the protein by heat treatment and / or treatment with trichloroacetic acid, etc., the extract obtained by centrifugation,
Glycogen is precipitated by adding an organic solvent such as methanol, ethanol, or acetone, or concentrated.
Glycogen can be recovered by spraying and drying.
【0016】本発明においては、カッコン(Puerariae
Radix)の抽出物及び抽出分画物の1種又は2種以上、
もしくは4',7-ジヒドロキシイソフラボンと、グリコー
ゲンとを皮膚外用剤基剤に含有させる。皮膚外用剤全量
あたりの配合量としては、カッコン(Puerariae Radi
x)の抽出物又は抽出分画物についてはその調製方法に
より異なるが、0.0001〜5.0重量%程度、4',7
-ジヒドロキシイソフラボンについては0.00001
〜0.1重量%程度、グリコーゲンについては0.00
1〜5.0重量%程度とするのが適切である。In the present invention, the cucumber ( Puerariae)
One or more extracts and extract fractions of Radix ),
Alternatively, 4 ′, 7-dihydroxyisoflavone and glycogen are contained in a skin external preparation base. For the total amount of skin preparation for external use, parentheses ( Puerariae Radi
The extract or extract fraction of x ) differs depending on the preparation method, but is about 0.0001 to 5.0% by weight,
0.00001 for dihydroxyisoflavone
About 0.1% by weight, and about 0.001 for glycogen
It is appropriate that the content be about 1 to 5.0% by weight.
【0017】本発明に係る皮膚外用剤は、ローション
剤,乳剤,ゲル剤,クリーム剤,軟膏剤,粉末剤,顆粒
剤等、種々の剤型で提供することができる。また、化粧
水,乳液,クリーム,美容液,パック等の皮膚化粧料、
メイクアップベースローション,メイクアップベースク
リーム等の下地化粧料、乳液状,油性,固形状等の各剤
型のファンデーション,アイカラー,チークカラー等の
メイクアップ化粧料、ハンドクリーム,レッグクリー
ム,ネッククリーム,ボディローション等の身体用化粧
料等として提供することができる。The external preparation for skin according to the present invention can be provided in various dosage forms such as lotions, emulsions, gels, creams, ointments, powders, granules and the like. Also, skin cosmetics such as lotion, milky lotion, cream, serum, pack, etc.
Base cosmetics such as makeup base lotion and makeup base cream, foundations of various dosage forms such as milky liquid, oily and solid, makeup cosmetics such as eye color and cheek color, hand cream, leg cream, neck cream , Body lotions and the like.
【0018】なお本発明に係る皮膚外用剤には、カッコ
ン(Puerariae Radix)抽出物等及びグリコーゲンの他
に、油性成分,界面活性剤,保湿剤,顔料,紫外線吸収
剤,抗酸化剤,香料,防菌防黴剤等の一般的な医薬品及
び化粧料用原料や、皮膚細胞賦活剤,抗炎症剤,美白剤
等の生理活性成分を含有させることができる。The external preparation for skin according to the present invention includes, in addition to the extract of Puerariae Radix, glycogen, oily components, surfactants, humectants, pigments, ultraviolet absorbers, antioxidants, fragrances, Raw materials for general pharmaceuticals and cosmetics such as antibacterial and fungicides, and physiologically active ingredients such as skin cell activators, anti-inflammatory agents, and whitening agents can be contained.
【0019】[0019]
【実施例】さらに本発明の特徴について、実施例により
詳細に説明する。EXAMPLES Further, the features of the present invention will be described in detail with reference to examples.
【0020】まず、本発明に係る皮膚外用剤に含有させ
るカッコン(Puerariae Radix)の抽出物及び抽出分画
物と、グリコーゲンの調製について示す。First, preparation of glycogen ( Puerariae Radix ) extract and extract fraction to be contained in the external preparation for skin according to the present invention will be described.
【0021】[カッコン抽出物1]カッコンの乾燥粉末
200gをエタノール1リットル中に浸漬し、20℃で
7日間静置して抽出し、抽出液をろ過して回収した後濃
縮,乾固し、凍結乾燥して、標記カッコン抽出物とし
た。[Cuckold extract 1] 200 g of dried cuckoo powder was immersed in 1 liter of ethanol, and allowed to stand at 20 ° C. for 7 days to extract. The extract was collected by filtration, concentrated, and dried. Lyophilized to give the title parentheses extract.
【0022】[カッコン抽出物2]カッコン500gを
細切し、エタノール2リットル中にて20℃で3日間撹
拌抽出し、抽出液をろ過して回収した後濃縮,乾固し、
グリセリン1リットルに溶解して、標記カッコン抽出物
とした。[Cuckold extract 2] 500 g of cuckoo is cut into small pieces, extracted with stirring in 2 liters of ethanol at 20 ° C. for 3 days, and the extract is collected by filtration, concentrated and dried.
It was dissolved in 1 liter of glycerin to obtain the title extract of parentheses.
【0023】[カッコン抽出物3]カッコン250gを
乾燥,粉砕し、50容量%エタノール水溶液2リットル
中にて20℃で7日間浸漬した後、ろ過してろ液を回収
して、カッコン抽出物3とした。[Brack extract 3] 250 g of bracken extract were dried and pulverized, immersed in 2 liters of a 50% by volume aqueous ethanol solution at 20 ° C. for 7 days, and then filtered to collect a filtrate. did.
【0024】[カッコン抽出分画物1〜4]カッコン
(Puerariae Radix)500gを乾燥,粉砕し、エタノ
ール2リットル中に浸漬して、20℃で7日間静置して
抽出した後、ろ過してろ液を回収し、次いで濃縮,乾固
して凍結乾燥する。この乾燥粉末36.0gをエタノー
ル500mlに溶解し、さらに精製水1500mlを加
え、600mlのDIAIONMCIゲル HP-20
(三菱化学株式会社製)を添加して1時間撹拌した後、
ろ過して前記樹脂を回収してカラムに充填し、水・エタ
ノールの混合溶媒にて順次段階的に溶出した。その際、
50容量%エタノール水溶液,70容量%エタノール水
溶液,90容量%エタノール水溶液及び99.5容量%
エタノール水溶液にて溶出される画分を回収し、それぞ
れ凍結乾燥して、標記抽出分画物1〜4とした。[Cuckon Extraction Fractions 1-4] 500 g of Puerariae Radix was dried, pulverized, immersed in 2 liters of ethanol, allowed to stand at 20 ° C. for 7 days, extracted, and filtered. The liquid is recovered, then concentrated, dried and freeze-dried. 36.0 g of this dry powder was dissolved in 500 ml of ethanol, and 1500 ml of purified water was added, and 600 ml of DIAION MCI gel HP-20 was added.
(Mitsubishi Chemical Corporation) and stirred for 1 hour,
The resin was collected by filtration, packed in a column, and eluted stepwise with a mixed solvent of water and ethanol. that time,
50 volume% ethanol aqueous solution, 70 volume% ethanol aqueous solution, 90 volume% ethanol aqueous solution and 99.5 volume%
Fractions eluted with an aqueous ethanol solution were collected and freeze-dried, respectively, to obtain fractionated extracts 1 to 4.
【0025】[ムラサキイガイ由来グリコーゲン]ムラ
サキイガイ(Mytilus edulis)の貝肉10kgに熱水5
リットルを加え15分間静置した後、コロイド破砕機に
より破砕する。前記破砕液を放冷した後、4℃にて8,
000rpmで5分間遠心分離し、上清に5重量%にな
るまでトリクロロ酢酸を加えてタンパク質を沈殿させて
ろ過し、ろ液をさらにメンブランフィルターにて除菌ろ
過し、濃縮した後、スプレードライヤーにより噴霧,乾
燥して得た。[Murasaki mussel-derived glycogen] 10 kg of mussel mussel ( Mytilus edulis ) shellfish meat and hot water 5
After adding the liter and leaving the mixture to stand for 15 minutes, the mixture is crushed by a colloid crusher. After allowing the crushed liquid to cool, at 4 ° C.
After centrifuging at 000 rpm for 5 minutes, trichloroacetic acid was added to the supernatant to 5% by weight to precipitate the protein, followed by filtration. The filtrate was further sterilized by a membrane filter, concentrated, and then concentrated by a spray drier. It was obtained by spraying and drying.
【0026】[トウモロコシ種子由来グリコーゲン]ト
ウモロコシ(Zea mays L.)の種子1kgを粉砕機で粉
砕し、精製水1kgを加えて混合し、室温で15分間撹
拌抽出する。抽出液をろ過してろ液を8,500rpm
にて5分間遠心分離し、上清を95℃で20分間加熱処
理し、冷却後、5,000rpmで5分間遠心分離して
凝固したタンパク質を除去した。上清を4℃に冷却し、
5重量%になるまでトリクロロ酢酸を加えてタンパク質
を沈殿させてろ過し、ろ液を3倍量のメタノールに注加
して生じた沈殿物を5,000rpmで5分間遠心分離
して回収し、メタノール,エタノール,ジエチルエーテ
ルで順次洗浄した後、凍結乾燥して得た。[Glycogen derived from corn seed] 1 kg of corn ( Zea mays L.) seeds are ground with a grinder, 1 kg of purified water is added and mixed, and the mixture is stirred and extracted at room temperature for 15 minutes. The extract is filtered and the filtrate is 8,500 rpm
The supernatant was heat-treated at 95 ° C. for 20 minutes, cooled, and centrifuged at 5,000 rpm for 5 minutes to remove the coagulated protein. Cool the supernatant to 4 ° C,
The protein was precipitated by adding trichloroacetic acid to 5% by weight and filtered. The filtrate was poured into three times the volume of methanol, and the resulting precipitate was collected by centrifugation at 5,000 rpm for 5 minutes. After washing with methanol, ethanol and diethyl ether successively, it was obtained by freeze-drying.
【0027】[米由来コラーゲン]精白米1kgを破砕
機にて粉砕し、精製水10リットルを加えて20℃で1
5分間撹拌抽出する。抽出液をろ過してろ液を8,50
0rpmにて5分間遠心分離し、上清を95℃で15分
間加熱処理し、冷却後、4,000rpmで5分間遠心
分離して凝固したタンパク質を除去した。上清を4℃に
冷却し、5重量%になるまでトリクロロ酢酸を加えてタ
ンパク質を沈殿させてろ過し、ろ液を3倍量のエタノー
ルに注加して生じた沈殿物を5,000rpmで5分間
遠心分離して回収し、メタノール,エタノール,ジエチ
ルエーテルで順次洗浄した後、凍結乾燥して得た。[Rice-derived collagen] 1 kg of polished rice is crushed by a crusher, and 10 liters of purified water is added thereto.
Stir and extract for 5 minutes. The extract is filtered and the filtrate is treated with 8,50.
After centrifugation at 0 rpm for 5 minutes, the supernatant was heat-treated at 95 ° C. for 15 minutes, cooled, and centrifuged at 4,000 rpm for 5 minutes to remove the coagulated protein. The supernatant was cooled to 4 ° C., and the protein was precipitated by adding trichloroacetic acid until the amount became 5% by weight, and the protein was filtered. The filtrate was poured into three times the volume of ethanol, and the resulting precipitate was collected at 5,000 rpm. It was collected by centrifugation for 5 minutes, washed sequentially with methanol, ethanol and diethyl ether, and then freeze-dried to obtain.
【0028】続いて、本発明に係る皮膚外用剤について
の実施例の処方を示す。Next, the formulations of the examples of the external preparation for skin according to the present invention will be shown.
【0029】 [実施例1] ローション剤 (1)エタノール 20.00(重量%) (2)ポリオキシエチレン(60E.O.)硬化ヒマシ油 1.00 (3)カッコン抽出物1 0.05 (4)ムラサキイガイ由来グリコーゲン 0.20 (5)パラオキシ安息香酸メチル 0.10 (6)ジプロピレングリコール 5.00 (7)1,3-ブチレングリコール 10.00 (8)精製水 63.65 製法:(1)に(2),(3)を添加して溶解し、アルコール相
とする。一方、(8)に(4)〜(7)を順次溶解して水相とす
る。水相にアルコール相を添加し、撹拌,混合する。[Example 1] Lotion agent (1) Ethanol 20.00 (% by weight) (2) Polyoxyethylene (60E.O.) hydrogenated castor oil 1.00 (3) Cuckoo extract 1 0.05 ( 4) Mussel mussel-derived glycogen 0.20 (5) Methyl paraoxybenzoate 0.10 (6) Dipropylene glycol 5.00 (7) 1,3-butylene glycol 10.00 (8) Purified water 63.65 Production method: ( Add (2) and (3) to 1) and dissolve to obtain alcohol phase. On the other hand, (4) to (7) are sequentially dissolved in (8) to form an aqueous phase. Add the alcohol phase to the aqueous phase, stir and mix.
【0030】 [実施例2] 乳剤 (1)セタノール 1.00(重量%) (2)ミツロウ 0.50 (3)ワセリン 2.00 (4)スクワラン 6.00 (5)ジメチルポリシロキサン 2.00 (6)ポリオキシエチレン(20E.O.)ソルビタン 1.00 モノステアリン酸エステル (7)グリセリルモノステアリン酸エステル 1.00 (8)グリセリン 4.00 (9)1,3-ブチレングリコール 4.00 (10)トウモロコシ種子由来グリコーゲン 0.10 (11)パラオキシ安息香酸メチル 0.10 (12)精製水 62.28 (13)カルボキシビニルポリマー 10.00 (1.0重量%水溶液) (14)水酸化カリウム(10.0重量%水溶液) 1.00 (15)エタノール 5.00 (16)カッコン抽出分画物1 0.02 製法:(1)〜(7)の油相成分を混合し、加熱溶解して75
℃とする。一方、(8)〜(12)の水相成分を混合,溶解し
て75℃とする。これに前記油相を加えて予備乳化した
後、(13)を添加してホモミキサーにて均一に乳化し、次
いで(14)を加えて増粘させた後冷却し、40℃で(16)を
(15)に溶解して添加,混合する。Example 2 Emulsion (1) Cetanol 1.00 (% by weight) (2) Beeswax 0.50 (3) Vaseline 2.00 (4) Squalane 6.00 (5) Dimethylpolysiloxane 2.00 (6) polyoxyethylene (20E.O.) sorbitan 1.00 monostearate (7) glyceryl monostearate 1.00 (8) glycerin 4.00 (9) 1,3-butylene glycol 4.00 (10) corn seed-derived glycogen 0.10 (11) methyl paraoxybenzoate 0.10 (12) purified water 62.28 (13) carboxyvinyl polymer 10.00 (1.0% by weight aqueous solution) (14) hydroxylation Potassium (10.0% by weight aqueous solution) 1.00 (15) Ethanol 5.00 (16) Bracken extract fraction 10.02 Production method: The oil phase components of (1) to (7) It was combined and heated to dissolve 75
° C. On the other hand, the aqueous phase components (8) to (12) are mixed and dissolved to 75 ° C. After the oil phase was added thereto and pre-emulsified, (13) was added thereto, and the mixture was uniformly emulsified with a homomixer, and then (14) was added to increase the viscosity, followed by cooling. To
Dissolve in (15), add and mix.
【0031】 [実施例3] 水中油型クリーム剤 (1)ミツロウ 6.00(重量%) (2)セタノール 5.00 (3)還元ラノリン 8.00 (4)スクワラン 27.50 (5)グリセリル脂肪酸エステル 4.00 (6)親油型グリセリルモノステアリン酸エステル 2.00 (7)ポリオキシエチレン(20E.O.)ソルビタン 5.00 モノラウリン酸エステル (8)プロピレングリコール 5.00 (9)パラオキシ安息香酸メチル 0.10 (10)カッコン抽出分画物2 0.02 (11)米由来グリコーゲン 0.25 (12)精製水 37.13 製法:(1)〜(7)の油相成分を混合,溶解して75℃とす
る。一方、(9),(10)を(8)に溶解して(11)とともに(12)
に加えて混合,溶解し、75℃に加熱する。次いで、こ
の水相成分に前記油相成分を添加して予備乳化した後ホ
モミキサーにて均一に乳化し、冷却する。Example 3 Oil-in-Water Cream (1) Beeswax 6.00 (% by weight) (2) Cetanol 5.00 (3) Reduced Lanolin 8.00 (4) Squalane 27.50 (5) Glyceryl Fatty acid ester 4.00 (6) Lipophilic glyceryl monostearate 2.00 (7) Polyoxyethylene (20E.O.) sorbitan 5.00 Monolaurate (8) Propylene glycol 5.00 (9) Paraoxy Methyl benzoate 0.10 (10) Cuckon extract fraction 2 0.02 (11) Rice-derived glycogen 0.25 (12) Purified water 37.13 Production method: Mix oil phase components (1) to (7) Dissolve to 75 ° C. On the other hand, (9) and (10) are dissolved in (8) and (12)
, Mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the aqueous phase component, preliminarily emulsified, then uniformly emulsified by a homomixer, and cooled.
【0032】 [実施例4] ゲル剤 (1)ジプロピレングリコール 10.00(重量%) (2)カルボキシビニルポリマー 0.50 (3)水酸化カリウム(10.0重量%水溶液) 1.00 (4)パラオキシ安息香酸メチル 0.10 (5)カッコン抽出分画物3 0.02 (6)ムラサキイガイ由来グリコーゲン 0.15 (7)精製水 88.23 製法:(7)に(2),(6)を均一に溶解した後、(1)に(4),
(5)を溶解して添加し、次いで(3)を加えて増粘させる。Example 4 Gel (1) Dipropylene glycol 10.00 (% by weight) (2) Carboxyvinyl polymer 0.50 (3) Potassium hydroxide (10.0% by weight aqueous solution) 1.00 ( 4) Methyl paraoxybenzoate 0.10 (5) Cracker extract fraction 3 0.02 (6) Mussel mussel-derived glycogen 0.15 (7) Purified water 88.23 Production method: (2), (6) ) Is dissolved uniformly, then (1) to (4),
(5) is dissolved and added, and then (3) is added to increase the viscosity.
【0033】 [実施例5] 水中油型乳剤型軟膏 (1)白色ワセリン 25.0(重量%) (2)ステアリルアルコール 25.0 (3)グリセリン 12.0 (4)ラウリル硫酸ナトリウム 1.0 (5)ムラサキイガイ由来グリコーゲン 0.1 (6)トウモロコシ種子由来グリコーゲン 0.1 (7)パラオキシ安息香酸メチル 0.1 (8)精製水 35.2 (9)カッコン抽出分画物4の1.0(w/v)% 1.5 エタノール溶液 製法:(1)〜(4)の油相成分を混合,加熱して均一に溶解
し、75℃とする。一方、(5)〜(8)の水相成分を混合,
加熱して75℃とする。この水相成分に前記油相成分を
撹拌しながら徐々に添加して乳化し、冷却した後、40
℃にて(9)を添加,混合する。[Example 5] Oil-in-water emulsion ointment (1) White petrolatum 25.0 (wt%) (2) Stearyl alcohol 25.0 (3) Glycerin 12.0 (4) Sodium lauryl sulfate 1.0 (5) Glycogen derived from mussels 0.1 (6) Glycogen derived from corn 0.1 0.1 (7) Methyl paraoxybenzoate 0.1 (8) Purified water 35.2 (9) 1.0 of extract 4 of cuckoo extract (w / v)% 1.5 Ethanol solution Production method: Mix and heat the oil phase components of (1) to (4) to uniformly dissolve, and bring to 75 ° C. On the other hand, the aqueous phase components (5) to (8) are mixed,
Heat to 75 ° C. The oil phase component was gradually added to the water phase component with stirring to emulsify, and after cooling, 40
Add (9) at ℃ and mix.
【0034】 [実施例6] リポソーム剤 (1)グリセリン 2.0(重量%) (2)1,3-ブチレングリコール 3.0 (3)ポリオキシエチレン(25E.O.)オレイルエーテル 0.2 (4)エタノール 10.0 (5)パラオキシ安息香酸メチル 0.1 (6)精製水 79.7 (7)4',7-ジヒドロキシイソフラボン,ムラサキ 5.0 イガイ由来グリコーゲン内包リポソーム 製法:(5)を(4)に溶解し、(1)〜(3)とともに(6)に添加
して均一に混合し、これに(7)を加えて分散する。な
お、(7)の4',7-ジヒドロキシイソフラボン,ムラサキイ
ガイ由来グリコーゲン内包リポソームは、4',7-ジヒド
ロキシイソフラボンを1.0(w/v)%含有する50容量
%エタノール水溶液50mlと、ムラサキイガイ由来グ
リコーゲンの2.5(w/v)%水溶液50mlに、大豆レ
シチン80gを添加して55℃で懸濁し、次いで超音波
処理してリポソームを調製し、遠心分離により回収して
得た。Example 6 Liposome preparation (1) Glycerin 2.0 (% by weight) (2) 1,3-butylene glycol 3.0 (3) Polyoxyethylene (25E.O.) oleyl ether 0.2 (4) Ethanol 10.0 (5) Methyl parahydroxybenzoate 0.1 (6) Purified water 79.7 (7) 4 ', 7-dihydroxyisoflavone, Murasaki 5.0 Mussel-derived liposome-encapsulated liposome Preparation method: (5) Is dissolved in (4), added to (6) together with (1) to (3), mixed uniformly, and dispersed by adding (7) thereto. The glycogen-encapsulated liposomes derived from 4 ′, 7-dihydroxyisoflavone and mussels in (7) are obtained by mixing 50 ml of a 50% by volume aqueous ethanol solution containing 1.0 (w / v)% of 4 ′, 7-dihydroxyisoflavone with mussels derived from mussels. 80 g of soybean lecithin was added to 50 ml of a 2.5% (w / v) aqueous solution of glycogen, suspended at 55 ° C., and then sonicated to prepare liposomes, which were recovered by centrifugation.
【0035】 [実施例7] 油中水型エモリエントクリーム (1)流動パラフィン 30.00(重量%) (2)マイクロクリスタリンワックス 2.00 (3)ワセリン 5.00 (4)ジグリセリルジオレイン酸エステル 5.00 (5)L-グルタミン酸ナトリウム 1.60 (6)L-セリン 0.40 (7)プロピレングリコール 3.00 (8)パラオキシ安息香酸メチル 0.10 (9)カッコン抽出物2 0.50 (10)米由来グリコーゲン 0.02 (11)精製水 52.28 (12)香料 0.10 製法:(5),(6)を(11)の一部に溶解して50℃とし、あ
らかじめ50℃に加温した(4)に撹拌しながら徐々に添
加する。これをあらかじめ混合し、70℃に加熱溶解し
た(1)〜(3)に均一に分散する。これに、(8),(9)を(7)
に溶解して(10)とともに(11)の残部に添加し、70℃に
加熱したものを撹拌しながら加え、ホモミキサーにて乳
化する。冷却後、40℃にて(12)を添加,混合する。[Example 7] Water-in-oil emollient cream (1) Liquid paraffin 30.00 (% by weight) (2) Microcrystalline wax 2.00 (3) Vaseline 5.00 (4) Diglyceryl dioleate Ester 5.00 (5) Sodium L-glutamate 1.60 (6) L-Serine 0.40 (7) Propylene glycol 3.00 (8) Methyl parahydroxybenzoate 0.10 (9) Cuckoo extract 20. 50 (10) Glycogen derived from rice 0.02 (11) Purified water 52.28 (12) Fragrance 0.10 Production method: Dissolve (5) and (6) in a part of (11) and bring to 50 ° C. The mixture is gradually added to (4) heated to 50 ° C. while stirring. This is mixed in advance, and is uniformly dispersed in (1) to (3) heated and dissolved at 70 ° C. In addition, (8), (9)
And added to the remainder of (11) together with (10), and the mixture heated to 70 ° C. is added with stirring and emulsified by a homomixer. After cooling, (12) is added and mixed at 40 ° C.
【0036】 [実施例8] メイクアップベースクリーム (1)ステアリン酸 12.00(重量%) (2)セタノール 2.00 (3)グリセリルトリ2-エチルヘキサン酸エステル 2.50 (4)自己乳化型グリセリルモノステアリン酸 2.00 エステル (5)プロピレングリコール 10.00 (6)トウモロコシ種子由来グリコーゲン 0.02 (7)水酸化カリウム 0.30 (8)パラオキシ安息香酸メチル 0.10 (9)精製水 67.48 (10)酸化チタン 2.00 (11)ベンガラ 0.40 (12)黄酸化鉄 0.10 (13)香料 0.10 (14)カッコン抽出物3 1.00 製法:(1)〜(4)の油相成分を混合,溶解して75℃とす
る。一方、(5)〜(9)の水相成分を混合,加熱溶解し、こ
れに(10)〜(12)の顔料成分を添加してホモミキサーにて
均一に分散して75℃とする。次いで、この水相成分に
前記油相成分を添加してホモミキサーにて均一に乳化
し、冷却後40℃にて(13),(14)を添加,混合する。Example 8 Makeup Base Cream (1) Stearic acid 12.00 (% by weight) (2) Cetanol 2.00 (3) Glyceryl tri-2-ethylhexanoate 2.50 (4) Self-emulsification Glyceryl monostearic acid 2.00 ester (5) Propylene glycol 10.00 (6) Corn seed-derived glycogen 0.02 (7) Potassium hydroxide 0.30 (8) Methyl parahydroxybenzoate 0.10 (9) Purification Water 67.48 (10) Titanium oxide 2.00 (11) Bengala 0.40 (12) Yellow iron oxide 0.10 (13) Fragrance 0.10 (14) Cuckon extract 3 1.00 Production method: (1) Mix and dissolve the oil phase components of (4) to (75). On the other hand, the aqueous phase components (5) to (9) are mixed and dissolved by heating, and the pigment components (10) to (12) are added thereto and uniformly dispersed by a homomixer to 75 ° C. Next, the oil phase component is added to the water phase component, and the mixture is uniformly emulsified by a homomixer. After cooling, (13) and (14) are added and mixed at 40 ° C.
【0037】 [実施例9] 乳液状ファンデーション (1)ステアリン酸 2.00(重量%) (2)スクワラン 5.00 (3)ミリスチン酸オクチルドデシル 5.00 (4)セタノール 1.00 (5)デカグリセリルモノイソパルミチン酸エステル 9.00 (6)1,3-ブチレンクリコール 6.00 (7)パラオキシ安息香酸メチル 0.10 (8)カッコン抽出物1 0.01 (9)米由来グリコーゲン 0.05 (10)水酸化カリウム 0.08 (11)精製水 53.51 (12)酸化チタン 9.00 (13)タルク 7.40 (14)ベンガラ 0.50 (15)黄酸化鉄 1.10 (16)黒酸化鉄 0.10 (17)香料 0.15 製法:(1)〜(5)の油相成分を混合,溶解して75℃とす
る。一方、(7),(8)を(6)に溶解して(9),(10)とともに
(11)に加えて混合,加熱溶解し、これに(12)〜(16)の顔
料成分を添加してホモミキサーにて均一に分散して75
℃とする。次いで、この水相成分に前記油相成分を添加
してホモミキサーにて均一に乳化し、冷却後40℃にて
(17)を添加,混合する。Example 9 Emulsion Foundation (1) Stearic acid 2.00 (% by weight) (2) Squalane 5.00 (3) Octyldodecyl myristate 5.00 (4) Cetanol 1.00 (5) Decaglyceryl monoisopalmitate 9.00 (6) 1,3-butylene crychol 6.00 (7) Methyl parahydroxybenzoate 0.10 (8) Cuckon extract 1 0.01 (9) Rice-derived glycogen 0 0.05 (10) Potassium hydroxide 0.08 (11) Purified water 53.51 (12) Titanium oxide 9.00 (13) Talc 7.40 (14) Bengala 0.50 (15) Yellow iron oxide 1.10 (16) Black iron oxide 0.10 (17) Fragrance 0.15 Production method: Mix and dissolve oil phase components (1) to (5) to 75 ° C. On the other hand, (7) and (8) are dissolved in (6) and (9) and (10)
In addition to (11), mix and heat dissolve, add the pigment components of (12) to (16) and uniformly disperse with a homomixer to 75
° C. Next, the oil phase component was added to the aqueous phase component, and the mixture was uniformly emulsified with a homomixer.
Add and mix (17).
【0038】 [実施例10] ハンドクリーム (1)セタノール 4.00(重量%) (2)ワセリン 2.00 (3)流動パラフィン 10.00 (4)グリセリルモノステアリン酸エステル 1.50 (5)ポリオキシエチレン(60E.O.)グリセリル 2.50 イソステアリン酸エステル (6)酢酸トコフェロール 0.25 (7)グリセリン 20.00 (8)パラオキシ安息香酸メチル 0.10 (9)カッコン抽出分画物1 0.02 (10)ムラサキイガイ由来グリコーゲン 0.05 (11)精製水 59.58 製法:(1)〜(6)の油相成分を混合,溶解して75℃とす
る。一方、(8),(9)を(7)に溶解して(10)とともに(11)
に加えて混合,溶解し、75℃とする。次いで、この水
相成分に前記油相成分を添加してホモミキサーにて均一
に乳化し、冷却する。Example 10 Hand Cream (1) Cetanol 4.00 (% by weight) (2) Vaseline 2.00 (3) Liquid paraffin 10.00 (4) Glyceryl monostearate 1.50 (5) Polyoxyethylene (60E.O.) glyceryl 2.50 Isostearate (6) Tocopherol acetate 0.25 (7) Glycerin 20.00 (8) Methyl parahydroxybenzoate 0.10 (9) Cuckon extract fraction 1 0.02 (10) Mussel mussel-derived glycogen 0.05 (11) Purified water 59.58 Production method: Mix and dissolve oil phase components (1) to (6) to 75 ° C. On the other hand, (8) and (9) are dissolved in (7) and (10) together with (11)
Then, mix and dissolve to 75 ° C. Next, the oil phase component is added to the aqueous phase component, uniformly emulsified by a homomixer, and cooled.
【0039】上記した本発明に係る実施例のうち、実施
例1〜実施例6について、中波長紫外線(UVB)によ
る皮膚のしわ形成に対する抑制効果を評価した。その際
実施例1〜実施例6において、それぞれ配合したカッコ
ン抽出物又は分画物及び各種グリコーゲン、或いは4',7
-ジヒドロキシイソフラボン,ムラサキイガイ由来グリ
コーゲン内包リポソームを、表1に示すように代替して
比較例1〜比較例6とし、同時に評価を行った。評価
は、ヘアレスマウス5匹を1群とし、各群について実施
例及び比較例をそれぞれ0.2gずつ1日1回背部に塗
布し、100mJ/cm2/回のUVBを1週間に3
回、20週間照射し、ヘアレスマウス皮膚におけるしわ
の形成状況を観察し、表2に示す判定基準に従って点数
化して評価した。この際、精製水のみを塗布した群を対
照とした。結果は各群の平均値を算出し、UVB照射日
数との関係により表3に示した。Among the above-mentioned examples according to the present invention, the effect of suppressing the formation of wrinkles on the skin by medium wavelength ultraviolet (UVB) was evaluated for Examples 1 to 6. At that time, in Example 1 to Example 6, each of the blended cuckoo extract or fraction and various glycogens, or 4 ′, 7
-Dihydroxyisoflavone and mussel-derived glycogen-encapsulated liposomes were replaced as shown in Table 1 as Comparative Examples 1 to 6 and evaluated simultaneously. For evaluation, five hairless mice were used as one group, and 0.2 g of each of Examples and Comparative Examples for each group was applied to the back once a day, and 100 mJ / cm 2 / time of UVB was applied 3 times a week.
Irradiation was performed 20 times for 20 weeks, and the formation of wrinkles on the skin of the hairless mouse was observed. At this time, a group to which only purified water was applied was used as a control. The results were calculated as the average value of each group, and shown in Table 3 in relation to the number of UVB irradiation days.
【0040】[0040]
【表1】 [Table 1]
【0041】[0041]
【表2】 [Table 2]
【0042】[0042]
【表3】 [Table 3]
【0043】表3より明らかなように、対照において
は、UVB照射日数が10週を越える頃には皮膚に形成
されたしわの深さは中程度にまで達し、20週後には深
いしわの形成が認められていた。カッコン抽出分画物4
とムラサキイガイ由来グリコーゲン,トウモロコシ種子
由来グリコーゲンのすべてを精製水に代替した比較例5
塗布群では、対照と比べて有意なしわの形成抑制効果は
見られていなかった。カッコンの抽出物又は抽出分画
物、ムラサキイガイ由来グリコーゲン又はトウモロコシ
種子由来グリコーゲンのいずれかを精製水に代替した比
較例1〜比較例4、及び4',7-ジヒドロキシイソフラボ
ンのみを内包するリポソームを含有する比較例6塗布群
では、20週後に軽微なしわの形成が認められる程度
で、しわの形成は良好に抑制されていたが、実施例塗布
群ではいずれも20週後に微小なしわの形成が認められ
た程度で、それぞれ対応する比較例塗布群に比べて、し
わ形成に対する抑制効果は有意に向上していた。As is clear from Table 3, in the control, the depth of wrinkles formed on the skin reached a medium level when the number of UVB irradiation days exceeded 10 weeks, and deep wrinkles formed after 20 weeks. Was recognized. Bracken extract fraction 4
Comparative Example 5 in which glycogen derived from mussels and mussel and glycogen derived from corn seed were all replaced with purified water
In the application group, no significant wrinkle formation inhibitory effect was observed compared to the control. Comparative Example 1 to Comparative Example 4 in which any of the extract or extract fraction of cuckoo, glycogen derived from mussel or corn seed derived glycogen was replaced with purified water, and containing liposomes containing only 4 ′, 7-dihydroxyisoflavone In Comparative Example 6 applied group, the formation of slight wrinkles was observed only after 20 weeks, and the formation of wrinkles was well suppressed. However, in the applied group of Examples, the formation of fine wrinkles was observed after 20 weeks. To the extent observed, the suppression effect on wrinkle formation was significantly improved as compared to the corresponding comparative group.
【0044】続いて、本発明の実施例1〜実施例10に
ついて使用試験を行い、皮膚の老化症状の改善効果を評
価した。その際、実施例7〜実施例10において、配合
したカッコン抽出物又は抽出分画物及び各種グリコーゲ
ンを表4に示すように代替して比較例7〜比較例10と
し、上記比較例1〜比較例6とともに同時に使用試験に
供した。Subsequently, use tests were conducted on Examples 1 to 10 of the present invention to evaluate the effect of improving the aging symptoms of the skin. At that time, in Examples 7 to 10, the blended cuckoo extract or extracted fraction and various glycogens were replaced as shown in Table 4 to make Comparative Examples 7 to 10 and Comparative Examples 1 to 10 described above. A use test was conducted simultaneously with Example 6.
【0045】[0045]
【表4】 [Table 4]
【0046】皮膚の老化症状の改善効果は、小じわ形成
及び皮膚弾性の低下が顕著に認められる40才代〜60
才代の女性パネラー20名を1群とし、各群に実施例及
び比較例のそれぞれをブラインドにて1日2回、2カ月
間連続して使用させて評価した。小じわの程度について
は肉眼観察及び写真撮影により評価し、皮膚弾性につい
てはキュートメーターにより測定して、それぞれ使用試
験開始前及び終了後の状態を比較し、「改善」,「やや
改善」,「変化なし」の3段階で評価した。結果は、各
評価を得たパネラー数にて表5に示した。The effect of improving the aging of the skin is from 40s to 60s, in which fine wrinkles are formed and skin elasticity is remarkably reduced.
Twenty-year-old female panelists were grouped into one group, and each group was evaluated using each of the examples and comparative examples twice a day continuously for two months using a blind. The degree of fine wrinkles was evaluated by visual observation and photography, and skin elasticity was measured with a cute meter. The conditions before and after the start of the use test were compared, and the results were "improved", "slightly improved", and "changed". None ". The results are shown in Table 5 by the number of panelists who obtained each evaluation.
【0047】[0047]
【表5】 [Table 5]
【0048】表5より明らかなように、カッコン抽出分
画物,ムラサキイガイ由来グリコーゲン及びトウモロコ
シ種子由来グリコーゲンのすべてを精製水に代替した比
較例5使用群を除いて、他の比較例使用群のそれぞれに
おいてもほぼ良好なしわ及び皮膚弾性の改善傾向が認め
られていたが、実施例使用群においては、それぞれ対応
する比較例使用群に比べて、明確な改善を認めたパネラ
ーは有意に多くなっていた。As is clear from Table 5, each of the groups used in Comparative Examples except for the group used in Comparative Example 5 except that all of the extract from the cuckoo, glycogen derived from mussel and glycogen derived from corn seed were replaced with purified water. Although almost good wrinkles and improvement tendencies in skin elasticity were also observed, the number of panelists who showed a clear improvement was significantly greater in the group using the examples than in the corresponding groups using the corresponding comparative examples. Was.
【0049】また、本発明の実施例1〜実施例10及び
比較例1〜比較例10について、肌荒れ症状の改善効果
を評価した。肌荒れ症状の改善効果は、顕著な肌荒れ症
状を呈する20才代〜60才代の女性パネラー20名を
1群とし、各群に実施例及び比較例のそれぞれをブライ
ンドにて1日2回、2カ月間連続して使用させて評価し
た。使用試験開始前及び終了後の皮膚の状態を、表6に
示す評価基準に従って評価,点数化し、20名の平均値
を算出して表7に示した。Further, the effects of the present invention for improving skin roughness symptoms were evaluated for Examples 1 to 10 and Comparative Examples 1 to 10. The effect of improving the skin roughness symptoms was as follows. Twenty female panelists in their twenties to sixties who exhibited remarkable skin roughness symptoms were grouped into one group, and each group was blinded with each of the Examples and Comparative Examples twice daily. The evaluation was performed by using continuously for months. The skin condition before and after the start of the use test was evaluated and scored according to the evaluation criteria shown in Table 6, and the average value of 20 persons was calculated and shown in Table 7.
【0050】[0050]
【表6】 [Table 6]
【0051】[0051]
【表7】 [Table 7]
【0052】表7より明らかなように、本発明の実施例
使用群ではいずれにおいても顕著な肌荒れの改善が認め
られ、使用試験終了後において、皮膚の状態はほぼ良好
な状態まで改善されていた。これに対し比較例使用群に
おいても、比較例5使用群を除きかなり良好な肌荒れの
改善が認められていたが、その程度はそれぞれ対応する
実施例使用群に比べて小さいものであった。As is evident from Table 7, in each of the groups using the examples of the present invention, remarkable improvement in skin roughness was observed, and after the use test, the skin condition was improved to an almost satisfactory state. . On the other hand, in the group using the comparative example, quite good improvement of the skin roughness was observed except for the group using the comparative example 5, but the degree was smaller than that of the corresponding group using the example.
【0053】なお実施例1〜実施例10については、2
5℃で6カ月間保存した場合において状態の変化は全く
認められず、男性パネラー30名による48時間の背部
閉塞貼付試験においても、問題となる皮膚刺激性反応は
認められなかった。In Examples 1 to 10, 2
When stored at 5 ° C. for 6 months, no change in the condition was observed, and no problematic skin irritation was observed in a 48-hour back obstruction sticking test by 30 male panelists.
【0054】[0054]
【発明の効果】以上詳述したように、本発明により、安
定性及び安全性が良好で、肌荒れ及び皮膚の老化の防
止,改善効果が相乗的に向上した皮膚外用剤を得ること
ができた。As described in detail above, according to the present invention, an external preparation for skin having good stability and safety, and synergistically improved prevention and improvement of skin roughness and skin aging can be obtained. .
【手続補正書】[Procedure amendment]
【提出日】平成13年9月4日(2001.9.4)[Submission date] September 4, 2001 (2001.9.4)
【手続補正1】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】0027[Correction target item name] 0027
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【0027】 [米由来グリコーゲン]精白米1kgを
破砕機にて粉砕し、精製水10リットルを加えて20℃
で15分間撹拌抽出する。抽出液をろ過してろ液を8,
500rpmにて5分間遠心分離し、上清を95℃で1
5分間加熱処理し、冷却後、4,000rpmで5分間
遠心分離して凝固したタンパク質を除去した。上清を4
℃に冷却し、5重量%になるまでトリクロロ酢酸を加え
てタンパク質を沈殿させてろ過し、ろ液を3倍量のエタ
ノールに注加して生じた沈殿物を5,000rpmで5
分間遠心分離して回収し、メタノール,エタノール,ジ
エチルエーテルで順次洗浄した後、凍結乾燥して得た。[0027] [US-derived glycoside Gen] was ground in a crusher polished rice 1 kg, 20 ° C. by adding purified 10 l water
And extract with stirring for 15 minutes. The extract is filtered and the filtrate is 8,
Centrifuge at 500 rpm for 5 minutes.
The mixture was heated for 5 minutes, cooled, and centrifuged at 4,000 rpm for 5 minutes to remove the coagulated protein. 4 supernatant
C., and the protein was precipitated by adding trichloroacetic acid until the weight became 5% by weight, and the protein was filtered. The filtrate was poured into three times the volume of ethanol, and the resulting precipitate was dried at 5,000 rpm for 5 minutes.
The solution was collected by centrifugation for 1 minute, washed sequentially with methanol, ethanol and diethyl ether, and then freeze-dried to obtain.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/715 A61K 31/715 35/56 35/56 A61P 29/00 A61P 29/00 43/00 107 43/00 107 Fターム(参考) 4C083 AA071 AA082 AA111 AB032 AB232 AB242 AB432 AC012 AC022 AC072 AC102 AC122 AC182 AC242 AC352 AC402 AC422 AC432 AC482 AC582 AC782 AC841 AC842 AD092 AD152 AD211 AD212 AD512 AD662 CC05 CC11 CC12 DD22 DD33 DD41 DD45 EE12 4C086 AA01 BA08 EA20 MA02 MA04 MA16 MA27 MA63 NA14 ZA89 ZB11 ZB22 4C087 AA01 BB13 CA06 MA02 MA17 MA22 MA24 MA28 MA63 NA14 ZA89 ZB11 ZB22 4C088 AB59 AC11 BA08 CA03 MA04 MA17 MA22 MA24 MA28 MA63 NA14 ZA89 ZB11 ZB22 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification code FI Theme coat ゛ (Reference) A61K 31/715 A61K 31/715 35/56 35/56 A61P 29/00 A61P 29/00 43/00 107 43 / 00 107 F-term (reference) 4C083 AA071 AA082 AA111 AB032 AB232 AB242 AB432 AC012 AC022 AC072 AC102 AC122 AC182 AC242 AC352 AC402 AC422 AC432 AC482 AC582 AC782 AC841 AC842 AD092 AD152 AD211 AD212 AD512 AD662 CC05 CC11 CC12 DD22 DD33 DD01 DD08 DD08 MA02 MA04 MA16 MA27 MA63 NA14 ZA89 ZB11 ZB22 4C087 AA01 BB13 CA06 MA02 MA17 MA22 MA24 MA28 MA63 NA14 ZA89 ZB11 ZB22 4C088 AB59 AC11 BA08 CA03 MA04 MA17 MA22 MA24 MA28 MA63 NA14 ZA89 ZB11 ZB22
Claims (4)
及び抽出分画物より選択した1種又は2種以上と、グリ
コーゲンとを含有して成る、皮膚外用剤。An external preparation for skin, comprising one or more selected from extracts and extract fractions of cuckoo ( Puerariae Radix ) and glycogen.
画物が、抽出物をイオン交換吸着樹脂に吸着させた後、
水・エタノール混合溶媒にて順次溶出した際、50容量
%〜99.5容量%エタノール水溶液により溶出される
画分であることを特徴とする、請求項1に記載の皮膚外
用剤。2. An extract fraction of cuckoo ( Puerariae Radix ), after the extract is adsorbed on an ion exchange adsorption resin,
The external preparation for skin according to claim 1, characterized in that, when sequentially eluted with a mixed solvent of water and ethanol, the fraction is eluted with 50% by volume to 99.5% by volume of an aqueous ethanol solution.
リコーゲンとを含有して成る、皮膚外用剤。3. An external preparation for skin comprising 4 ', 7-dihydroxyisoflavone and glycogen.
ものであることを特徴とする、請求項1〜請求項3に記
載の皮膚外用剤。4. The external preparation for skin according to claim 1, wherein the glycogen is extracted from mussels.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001127151A JP3643785B2 (en) | 2001-04-25 | 2001-04-25 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001127151A JP3643785B2 (en) | 2001-04-25 | 2001-04-25 | Topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002322078A true JP2002322078A (en) | 2002-11-08 |
| JP3643785B2 JP3643785B2 (en) | 2005-04-27 |
Family
ID=18976071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001127151A Expired - Fee Related JP3643785B2 (en) | 2001-04-25 | 2001-04-25 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3643785B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016111265A1 (en) * | 2015-01-08 | 2016-07-14 | 江崎グリコ株式会社 | Antioxidant agent, and antioxidant cosmetic and uv care cosmetic |
-
2001
- 2001-04-25 JP JP2001127151A patent/JP3643785B2/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016111265A1 (en) * | 2015-01-08 | 2016-07-14 | 江崎グリコ株式会社 | Antioxidant agent, and antioxidant cosmetic and uv care cosmetic |
| JPWO2016111265A1 (en) * | 2015-01-08 | 2017-10-19 | 江崎グリコ株式会社 | Antioxidants and antioxidant / UV care cosmetics |
| US10286005B2 (en) | 2015-01-08 | 2019-05-14 | Ezaki Glico Co., Ltd. | Antioxidant agent, and antioxidant cosmetic and UV care cosmetic |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3643785B2 (en) | 2005-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000044485A (en) | Active oxygen species scavenger and skin cosmetic | |
| JPS5916816A (en) | External composition | |
| JP2003104865A (en) | Skin care preparation | |
| JP2002370922A (en) | Cosmetics containing plum extract | |
| JP3667027B2 (en) | Topical skin preparation | |
| JP2001114636A (en) | Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion | |
| KR100372360B1 (en) | Cosmetic compositions containing garlic and Acanthopanax extracts | |
| JP2001348338A (en) | Collagen production promoter and skin care preparation for preventing skin aging comprising the same | |
| KR101736716B1 (en) | Cosmetic composition for skin elasticity and anti-wrinkle comprising plants extract | |
| JPH10194982A (en) | Collagenase inhibitor and skin lotion for senescence prevention containing the same | |
| JP2003137742A (en) | Hair growing agent comprising evolvulus plant extract and other galenical extract | |
| JP3449967B2 (en) | External preparation for skin | |
| JP2002104952A (en) | External preparation for skin | |
| JP3643788B2 (en) | Topical skin preparation | |
| JP3643785B2 (en) | Topical skin preparation | |
| JP2003335651A (en) | Skin care preparation for external use | |
| JP2002363091A (en) | Skin care preparation | |
| JP2002037709A (en) | Skin care preparation | |
| JPH10236941A (en) | Skin lotion | |
| JP2002370999A (en) | Skin care preparation | |
| JP2002097149A (en) | Skin care preparation | |
| JP2003335625A (en) | External preparation for skin | |
| JPS61254510A (en) | External agent for skin | |
| JP2003267851A (en) | Skin care preparation | |
| JP2003335628A (en) | Skin care preparation for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040730 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040928 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7421 Effective date: 20041014 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041015 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041015 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050114 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050131 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 3643785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080204 Year of fee payment: 3 |
|
| RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D05 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090204 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100204 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100204 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110204 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120204 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120204 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130204 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140204 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |